Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): A randomised, multicentre, open-label phase 3 trial

The Lancet

Volumn 385, Issue 9980, 2015, Pages 1873-1883

  Hillmen, Peter ^a   Robak, Tadeusz ^b   Janssens, Ann ^c   Babu, K Govind ^d   Kloczko, Janusz ^e   Grosicki, Sebastian ^f   Doubek, Michael ^g   Panagiotidis, Panagiotis ^h   Kimby, Eva ⁱ   Schuh, Anna ^j   Pettitt, Andrew R ^k   Boyd, Thomas ^l   Montillo, Marco ^m   Gupta, Ira V ^o   Wright, Oliver ⁿ   Dixon, Iestyn ⁿ   Carey, Jodi L ^o   Chang, Chai Ni ^o   Lisby, Steen ^p   McKeown, Astrid ⁿ   Offner, Fritz ^q   more..

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d KIDWAI MEMORIAL INSTITUTE OF ONCOLOGY   (India)

^e MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^f MEDICAL UNIVERSITY OF SILESIA   (Poland)

^g UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^h UNIVERSITY OF ATHENS   (Greece)

ⁱ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^j CHURCHILL HOSPITAL   (United Kingdom)

^k UNIVERSITY OF LIVERPOOL   (United Kingdom)

^l Yakima Valley Memorial Hospital   (United States)

^m OSPEDALE NIGUARDA CA GRANDA   (Italy)

ⁿ GLAXOSMITHKLINE   (United Kingdom)

^o GLAXOSMITHKLINE   (United States)

^p Genmab   (Denmark)

^q GHENT UNIVERSITY HOSPITAL   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMBUCIL; OFATUMUMAB; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHILL; CHRONIC LYMPHATIC LEUKEMIA; COMORBIDITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; HYPOTENSION; INFUSION RELATED REACTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OPEN STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; AGE DISTRIBUTION; CLINICAL TRIAL; DRUG ADMINISTRATION; KAPLAN MEIER METHOD; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; SEX RATIO; VERY ELDERLY;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHLORAMBUCIL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEX DISTRIBUTION; TREATMENT OUTCOME;

EID: 84929505415     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)60027-7     Document Type: Article

References (36)

1. I Del Giudice, FR Mauro, R Foa Chronic lymphocytic leukemia in less fit patients: "slow-go" Leuk Lymphoma 52 2011 2207 2216
2. KA Foon, D Mehta, S Lentzsch et al. Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia Blood 119 2012 3184 3185
3. F Forconi, A Fabbri, M Lenoci et al. Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia Hematol Oncol 26 2008 247 251
4. K Fischer, P Cramer, R Busch et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group J Clin Oncol 30 2012 3209 3216
5. WU Knauf, T Lissichkov, A Aldaoud et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia J Clin Oncol 27 2009 4378 4384
6. BF Eichhorst, R Busch, S Stilgenbauer et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia Blood 114 2009 3382 3391
7. JA Woyach, AS Ruppert, K Rai et al. Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential Cancer and Leukemia Group B studies J Clin Oncol 31 2012 440 447
8. JL Teeling, WJM Mackus, LJJM Wiegman et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20 J Immunol 177 2006 362 371
9. PV Beum, MA Lindorfer, F Beurskens et al. Complement activation on B Lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis J Immunol 181 2008 822 832
10. JL Craigen, WJM Mackus, P Engleberts et al. Ofatumumab, a human mab targeting a membrane-proximal small-loop epitope on CD20, induces potent NK cell-mediated ADCC Blood 114 2009 abstract 1725.
11. M Okroj, I Eriksson, A Österborg, A Blom Killing of CLL and NHL cells by rituximab and ofatumumab under limited availability of complement Med Oncol 30 2013 1 8
12. S Rafiq, JP Butchar, C Cheney et al. Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties J Immunol 190 2013 2702 2711
13. JL Teeling, RR French, MS Cragg et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas Blood 104 2004 1793 1800
14. WG Wierda, TJ Kipps, J Mayer et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia J Clin Oncol 28 2010 1749 1755
15. WG Wierda, S Padmanabhan, GW Chan et al. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study Blood 118 2011 5126 5129
16. M Hallek, BD Cheson, D Catovsky et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute-Working Group (NCI-WG) 1996 guidelines Blood 111 2008 5446 5456
17. P Ghia, K Stamatopoulos, C Belessi et al. ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia Leukemia 21 2007 1 3
18. AC Rawstron, N Villamor, M Ritgen et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia Leukemia 21 2007 956 964
19. M Extermann, J Overcash, GH Lyman, J Parr, L Balducci Comorbidity and functional status are independent in older cancer patients J Clin Oncol 16 1998 1582 1587
20. MD Miller, CF Paradis, PR Houck et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale Psychiatry Res 41 1992 237 248
21. D Catovsky, S Richards, E Matutes et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial Lancet 370 2007 230 239
22. V Goede, K Fischer, R Busch et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions N Engl J Med 370 2014 1001 1010
23. F Salvi, MD Miller, A Grilli et al. A manual of guidelines to score the modified Cumulative Illness Rating Scale and its validation in acute hospitalized elderly patients J Am Geriatr Soc 56 2008 1926 1931
24. KA Blum, D Young, S Broering et al. Computed tomography scans do not improve the predictive power of 1996 National Cancer Institute sponsored Working Group chronic lymphocytic leukemia response criteria J Clin Oncol 25 2007 5624 5629
25. MJ Keating, S O'Brien, M Albitar et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia J Clin Oncol 23 2005 4079 4088
26. JC Byrd, K Rai, BL Peterson et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011 Blood 105 2005 49 53
27. B Eichhorst, V Goede, M Hallek Treatment of elderly patients with chronic lymphocytic leukemia Leuk Lymphoma 50 2009 171 178
28. P Hillmen, JG Gribben, GA Follows et al. Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: final analysis of an open-label phase ii study J Clin Oncol 32 2014 1236 1241
29. R Foà, I Del Giudice, A Cuneo et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients Am J Hematol 89 2014 480 486
30. WU Knauf, T Lissitchkov, A Aldaoud et al. Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial Br J Haematol 159 2012 67 77
31. P Hillmen, AB Skotnicki, T Robak et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia J Clin Oncol 25 2007 1656 1723
32. KR Rai, BL Peterson, FR Appelbaum et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia N Engl J Med 343 2000 1750 1757
33. AC Rawstron, S Bottcher, R Letestu et al. Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL Leukemia 27 2013 142 149
34. M Hallek, K Fischer, G Fingerle-Rowson et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial Lancet 376 2010 1164 1174
35. S Boettcher, M Ritgen, K Fischer et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from ther GCLLSG CLL8 Trial J Clin Oncol 30 2012 980 988
36. Offner F, Panagiotidis P, Afanasyev B, et al. Ofatumumab and bendamustine combination therapy in patients with untreated and relapsed chronic lymphocytic leukemia: initial results of the phase II study OMB115991. 15th International Workshop on Chronic Lymphocytic Leukaemia (iwCLL 2013); Cologne, Germany; September 9-11, 2013. Abstr 4.29.